First trimester exposure to Lyrica may be associated with an increased risk of major birth defects (MBDs)
20 mai 2016 par maty185
L’exposition durant le premier trimestre à la prégabaline peut être associée à un risque accru de malformations congénitales majeures (de MBDS), suggère une étude observationnelle.
First trimester exposure to pregabalin may be associated with an increased risk of major birth defects (MBDs), an observational study suggests.
The data from eight Teratology Information Services in seven countries on 164 exposed pregnancies showed that the risk of MBDs was increased a significant threefold compared with 656 unexposed pregnancies.
After limiting the findings to just first trimester exposure and excluding chromosomal aberration syndromes, the rate of major congenital malformations was 6.0% among 116 infants exposed to pregabalin as neonates versus 2.1% among 580 unexposed infants. These included four chromosomal and eight structural anomalies affecting the central nervous system (CNS), or the skeletal, cardiac, and skin or vascular systems.
« Our results raise a signal for a possible increase in the rate of MBD after pregabalin treatment during the first trimester of pregnancy », say researcher Ursula Winterfield (Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland) and colleagues.
The rate of CNS malformations alone was also significantly higher following pregabalin exposure, increased sixfold, at 3.2% compared with 0.5%.
Lyrica – Prégabaline – Pregabalin – Gabapentin – Gabapentine – GABOB – Baclofen – Phenibut